Akorn (AKRX) : The highest level Akorn (AKRX) is projected to reach is $40 for the short term and the lowest estimate is at $31. The consolidated price target from 8 rating analysts who initiate coverage on the stock is $35.75 and the possibility the share price can swing is $3.33.
Akorn (AKRX) : Zacks Investment Research ranks Akorn (AKRX) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 10 research analysts is 1.9, which indicates as a Buy.
Also, In a research note released to the investors, Deutsche Bank downgrades its rating on Akorn (NASDAQ:AKRX).The analysts at the brokerage house have a current rating of Hold on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on August 5, 2016.
Akorn (NASDAQ:AKRX): The stock opened at $27.04 on Thursday but the bulls could not build on the opening and the stock topped out at $27.10 for the day. The stock traded down to $26.21 during the day, due to lack of any buying support eventually closed down at $26.68 with a loss of -0.89% for the day. The stock had closed at $26.92 on the previous day. The total traded volume was 1,005,304 shares.
Akorn Inc. (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company operates in two segments: Prescription Pharmaceuticals, which is engaged in the sale of branded and generic prescription pharmaceuticals, and Consumer Health, which is engaged in the sale of branded and private label consumer and animal health products. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York, and Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, and an additional warehousing facility in Amityville, New York.